Nymox Pharmaceutical Corporation (NYMXF)
OTCMKTS
· Delayed Price · Currency is USD
0.120
+0.090 (300.00%)
Sep 17, 2024, 4:00 PM EDT
Nymox Pharmaceutical Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '23 Dec 31, 2023 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | - | - | - | - | 0.01 | 0.12 | Upgrade
|
| Revenue Growth (YoY) | - | - | - | - | -95.69% | -61.20% | Upgrade
|
| Cost of Revenue | - | - | - | - | 0 | 0.06 | Upgrade
|
| Gross Profit | - | - | - | - | 0 | 0.06 | Upgrade
|
| Selling, General & Admin | 4.36 | 4.36 | 2.88 | 5.85 | 3.6 | 6.01 | Upgrade
|
| Research & Development | 3.99 | 3.99 | 3.77 | 6.66 | 8.12 | 7.38 | Upgrade
|
| Operating Expenses | 8.35 | 8.35 | 6.65 | 12.5 | 11.72 | 13.38 | Upgrade
|
| Operating Income | -8.35 | -8.35 | -6.65 | -12.5 | -11.72 | -13.33 | Upgrade
|
| Interest Expense | -0.06 | -0.06 | -0.04 | -0.04 | -0.04 | -0.04 | Upgrade
|
| Interest & Investment Income | 0.01 | 0.01 | 0 | 0.01 | 0.03 | 0.21 | Upgrade
|
| Currency Exchange Gain (Loss) | 0 | 0 | 0.01 | -0 | -0 | -0.01 | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | 0.11 | - | - | - | Upgrade
|
| EBT Excluding Unusual Items | -8.4 | -8.4 | -6.58 | -12.54 | -11.74 | -13.16 | Upgrade
|
| Other Unusual Items | -0.44 | -0.44 | - | - | - | - | Upgrade
|
| Pretax Income | -8.84 | -8.84 | -6.58 | -12.54 | -11.74 | -13.16 | Upgrade
|
| Net Income | -8.84 | -8.84 | -6.58 | -12.54 | -11.74 | -13.16 | Upgrade
|
| Net Income to Common | -8.84 | -8.84 | -6.58 | -12.54 | -11.74 | -13.16 | Upgrade
|
| Shares Outstanding (Basic) | 92 | 92 | 89 | 82 | 74 | 69 | Upgrade
|
| Shares Outstanding (Diluted) | 92 | 92 | 89 | 82 | 74 | 69 | Upgrade
|
| Shares Change (YoY) | 2.58% | 2.58% | 9.03% | 11.04% | 7.23% | 13.86% | Upgrade
|
| EPS (Basic) | -0.10 | -0.10 | -0.07 | -0.15 | -0.16 | -0.19 | Upgrade
|
| EPS (Diluted) | -0.10 | -0.10 | -0.07 | -0.15 | -0.16 | -0.19 | Upgrade
|
| Free Cash Flow | -4.06 | -4.06 | -5.21 | -9.83 | -10.05 | -7.43 | Upgrade
|
| Free Cash Flow Per Share | -0.04 | -0.04 | -0.06 | -0.12 | -0.14 | -0.11 | Upgrade
|
| Gross Margin | - | - | - | - | 20.00% | 50.00% | Upgrade
|
| Operating Margin | - | - | - | - | -234400.00% | -11487.07% | Upgrade
|
| Profit Margin | - | - | - | - | -234760.00% | -11346.55% | Upgrade
|
| Free Cash Flow Margin | - | - | - | - | -201000.00% | -6405.17% | Upgrade
|
| EBITDA | -8.34 | -8.34 | -6.64 | -12.49 | -11.71 | -13.32 | Upgrade
|
| D&A For EBITDA | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | Upgrade
|
| EBIT | -8.35 | -8.35 | -6.65 | -12.5 | -11.72 | -13.33 | Upgrade
|
| Revenue as Reported | - | - | - | - | 0.01 | 0.12 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.